EPW
EBS icon

Evolve Private Wealth’s Emergent Biosolutions EBS Stock Holding History

Evolve Private Wealth’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$593K Buy
70,740
+4,986
+8% +$41.7K 0.04% 450
2026
Q1 		$546K Buy
+65,754
New +$681K 0.03% 538

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Evolve Private Wealth's EBS Position: Q2 2026 in Review

Evolve Private Wealth increased its Emergent Biosolutions (EBS) stake by 7.6% in Q2 2026, buying an estimated $41.7K and bringing the position to 70,740 shares worth $593K. The position accounts for 0.04% of the portfolio, ranked #450.

Evolve Private Wealth first reported a position in EBS in Q1 2026 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Evolve Private Wealth held 70,740 shares of Emergent Biosolutions worth $593K as of Q2 2026.
  • Evolve Private Wealth bought 4,986 Emergent Biosolutions shares in Q2 2026, an estimated $41.7K.
  • Emergent Biosolutions made up 0.04% of Evolve Private Wealth's portfolio in Q2 2026, its #450 holding.
  • Evolve Private Wealth first reported a position in Emergent Biosolutions in Q1 2026 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.